Cargando…
Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy
By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bear...
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Landes Bioscience
2013
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782009/ https://www.ncbi.nlm.nih.gov/pubmed/24073365 http://dx.doi.org/10.4161/onci.24720 |
| _version_ | 1782285505884323840 |
|---|---|
| author | Loi, Sherene |
| author_facet | Loi, Sherene |
| author_sort | Loi, Sherene |
| collection | PubMed |
| description | By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bearing HER2 over-expression. These findings suggest that immunomodulation could represent a new approach to treat these aggressive breast cancer subtypes. |
| format | Online Article Text |
| id | pubmed-3782009 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2013 |
| publisher | Landes Bioscience |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-37820092013-09-26 Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy Loi, Sherene Oncoimmunology Author's View By analyzing over 2000 samples from a randomized clinical trial, we have recently associated high levels of tumor-infiltrating lymphocytes with an excellent prognosis among triple negative breast cancer patients as well with improved clinical responses to immunogenic chemotherapy among patients bearing HER2 over-expression. These findings suggest that immunomodulation could represent a new approach to treat these aggressive breast cancer subtypes. Landes Bioscience 2013-07-01 2013-04-30 /pmc/articles/PMC3782009/ /pubmed/24073365 http://dx.doi.org/10.4161/onci.24720 Text en Copyright © 2013 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited. |
| spellingShingle | Author's View Loi, Sherene Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy |
| title | Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy |
| title_full | Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy |
| title_fullStr | Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy |
| title_full_unstemmed | Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy |
| title_short | Tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy |
| title_sort | tumor-infiltrating lymphocytes, breast cancer subtypes and therapeutic efficacy |
| topic | Author's View |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3782009/ https://www.ncbi.nlm.nih.gov/pubmed/24073365 http://dx.doi.org/10.4161/onci.24720 |
| work_keys_str_mv | AT loisherene tumorinfiltratinglymphocytesbreastcancersubtypesandtherapeuticefficacy |